/

Società

To

Non verificato

Topas Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieScienza

3 comunicati stampa

Guarda tutti i comunicati

24/04/2025

Eventi

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego

Fonte

Topas Therapeutics

Emittente

1.00

0

17/03/2025

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Topas Therapeutics Publishes Foundational Data Demonstrating Tolerance Induction by its Proprietary Nanoparticle Platform in Frontiers in Immunology

Fonte

Topas Therapeutics

Emittente

1.00

0

15/10/2024

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease

Fonte

Topas Therapeutics

Emittente

1.00

0

Seguaci

0

Compatibilità

0